戈利木单抗，一种完全人源化的抗肿瘤坏死因子α单克隆抗体。
Golimumab, a fully human monoclonal antibody against TNFalpha.
作者信息
Hutas Gabor
机构信息
Rush University Medical Center, Department of Orthopedic Surgery, MC102, Cohn Building, Room 712, 1735 W Harrison St, Chicago, IL 60612, USA.
出版信息
Curr Opin Mol Ther. 2008 Aug;10(4):393-406.
Centocor Inc and licensees Schering-Plough Corp, Mitsubishi Tanabe Pharma Corp and Janssen Pharmaceutical KK are developing golimumab, a fully human mAb antibody against TNFalpha, for the potential treatment of rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS) and ulcerative colitis. Golimumab is currently in phase III clinical trials for RA, PsA and AS and preliminary data have shown an improvement in a number of physical functions, disease activity, productivity and quality-of-life measurements.
Centocor公司及其被许可方先灵葆雅公司、三菱田边制药公司和杨森制药株式会社正在开发戈利木单抗，这是一种针对肿瘤坏死因子α（TNFα）的全人源单克隆抗体，用于潜在治疗类风湿性关节炎（RA）、银屑病关节炎（PsA）、强直性脊柱炎（AS）和溃疡性结肠炎。戈利木单抗目前正处于针对RA、PsA和AS的III期临床试验阶段，初步数据显示在一些身体功能、疾病活动、生产力和生活质量指标方面有所改善。
Zotero 插件